{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,31]],"date-time":"2025-08-31T10:10:01Z","timestamp":1756635001602,"version":"3.37.3"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Pharm"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1007\/s11096-018-0667-z","type":"journal-article","created":{"date-parts":[[2018,5,31]],"date-time":"2018-05-31T20:48:04Z","timestamp":1527799684000},"page":"997-1000","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Optimal timing for pegfilgrastim administration in Japanese breast cancer patients receiving intermediate-risk chemotherapies"],"prefix":"10.1007","volume":"40","author":[{"given":"Tatsuya","family":"Hayama","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenichi","family":"Sakurai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1538-3804","authenticated-orcid":false,"given":"Katsuhiro","family":"Miura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinsaku","family":"Washinosu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinya","family":"Tsuboi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akihiro","family":"Uchiike","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshikazu","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masami","family":"Takei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,6,1]]},"reference":[{"key":"667_CR1","doi-asserted-by":"publisher","first-page":"3199","DOI":"10.1200\/JCO.2015.62.3488","volume":"33","author":"TJ Smith","year":"2015","unstructured":"Smith TJ, Bohlke K, Lyman GH, Carson KR, Crawford J, Cross SJ, et al. Recommendations for the use of WBC growth factors: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2015;33:3199\u2013212.","journal-title":"J Clin Oncol"},{"key":"667_CR2","unstructured":"National Comprehensive Cancer Network (NCCN); The NCCN clinical practice guidelines in oncology: myeloid growth factors v2. 2017. October 13, 2017."},{"key":"667_CR3","doi-asserted-by":"publisher","first-page":"2107","DOI":"10.1080\/03007995.2017.1386858","volume":"33","author":"D Weycker","year":"2017","unstructured":"Weycker D, Bensink M, Lonshteyn A, Doroff R, Chandler D. Risk of chemotherapy-induced febrile neutropenia by day of pegfilgrastim prophylaxis in US clinical practice from 2010 to 2015. Curr Med Res Opin. 2017;33:2107\u201313.","journal-title":"Curr Med Res Opin"},{"key":"667_CR4","first-page":"4665","volume":"30","author":"T Shimizu","year":"2010","unstructured":"Shimizu T, Hirano A, Kamimura M, Ogura K, Kim N, Watanabe O, et al. A phase II study of epirubicin and cyclophosphamide followed by weekly paclitaxel with or without trastuzumab as primary systemic therapy in locally advanced breast cancer. Anticancer Res. 2010;30:4665\u201371.","journal-title":"Anticancer Res"},{"key":"667_CR5","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1056\/NEJMoa1113216","volume":"366","author":"J Baselga","year":"2012","unstructured":"Baselga J, Cort\u00e9s J, Kim S-B, Im S-A, Hegg R, Im Y-H, et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med. 2012;366:109\u201319.","journal-title":"N Engl J Med"},{"issue":"Suppl 1","key":"667_CR6","doi-asserted-by":"publisher","first-page":"S49","DOI":"10.1086\/383054","volume":"39","author":"T Masaoka","year":"2004","unstructured":"Masaoka T. Evidence-based recommendations for antimicrobial use in febrile neutropenia in Japan: executive summary. Clin Infect Dis. 2004;39(Suppl 1):S49\u201352.","journal-title":"Clin Infect Dis"},{"key":"667_CR7","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1093\/annonc\/mdg019","volume":"14","author":"MD Green","year":"2003","unstructured":"Green MD. A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy. Ann Oncol. 2003;14:29\u201335.","journal-title":"Ann Oncol"},{"key":"667_CR8","doi-asserted-by":"publisher","first-page":"1872","DOI":"10.1093\/annonc\/mdq674","volume":"22","author":"C Zwick","year":"2011","unstructured":"Zwick C, Hartmann F, Zeynalova S, Poschel V, Nickenig C, Reiser M, et al. Randomized comparison of pegfilgrastim day 4 versus day 2 for the prevention of chemotherapy-induced leukocytopenia. Ann Oncol. 2011;22:1872\u20137.","journal-title":"Ann Oncol"},{"key":"667_CR9","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1007\/s00520-010-1020-9","volume":"19","author":"S Loibl","year":"2011","unstructured":"Loibl S, Mueller V, von Minckwitz G, Conrad B, Koehne CH, Kremers S, et al. Comparison of pegfilgrastim on day 2 vs. day 4 as primary prophylaxis of intense dose-dense chemotherapy in patients with node-positive primary breast cancer within the prospective, multi-center GAIN study: (GBG 33). Support Care Cancer. 2011;19:1789\u201395.","journal-title":"Support Care Cancer"},{"key":"667_CR10","doi-asserted-by":"publisher","first-page":"2891","DOI":"10.1007\/s00520-015-2654-4","volume":"23","author":"N Masuda","year":"2015","unstructured":"Masuda N, Tokuda Y, Nakamura S, Shimazaki R, Ito Y, Tamura K. Dose response of pegfilgrastim in Japanese breast cancer patients receiving six cycles of docetaxel, doxorubicin, and cyclophosphamide therapy: a randomized controlled trial. Support Care Cancer. 2015;23:2891\u20138.","journal-title":"Support Care Cancer"}],"container-title":["International Journal of Clinical Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11096-018-0667-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-018-0667-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-018-0667-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T02:37:20Z","timestamp":1559356640000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11096-018-0667-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,1]]},"references-count":10,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,10]]}},"alternative-id":["667"],"URL":"https:\/\/doi.org\/10.1007\/s11096-018-0667-z","relation":{},"ISSN":["2210-7703","2210-7711"],"issn-type":[{"type":"print","value":"2210-7703"},{"type":"electronic","value":"2210-7711"}],"subject":[],"published":{"date-parts":[[2018,6,1]]},"assertion":[{"value":"22 January 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 May 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 June 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"K Miura received speaker\u2019s fees from Kyowa Hakko Kirin Co. Ltd., which manufactures pegfilgrastim in Japan. M. Takei received research grants from Kyowa Hakko Kirin Co. Ltd. The remaining authors have declared that they have no conflicts of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}